Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

712
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
712
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

955
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
955
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

792
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
792
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

1.3K
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
1.3K
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

492
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
492
Survival Curves01:18

Survival Curves

931
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
931

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caution: very high HDL-cholesterol.

Progress in cardiovascular diseases·2026
Same author

Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

JCO precision oncology·2026
Same author

Identifying Risk-De-Escalating Markers in PREVENT-Defined Intermediate-Risk Older Adults: Insights From ASPREE.

Circulation. Population health and outcomes·2026
Same author

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Future oncology (London, England)·2026
Same author

Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma.

Journal of the National Cancer Institute·2026
Same author

Semiparametric accelerated failure time models with time-varying covariates under partly interval censoring.

BMC medical research methodology·2026

Related Experiment Video

Updated: May 4, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.9K

Semiparametric methods for multistate survival models in randomised trials.

Harold M Hudson1, Serigne N Lô, R John Simes

  • 1NHMRC Clinical Trials Centre, University of Sydney, New South Wales 2006, Australia; The George Institute, University of Sydney, New South Wales 2050, Australia; Department of Statistics, Macquarie University, North Ryde, New South Wales 2109, Australia.

Statistics in Medicine
|December 17, 2013
PubMed
Summary

Transform methods effectively analyze event progression in semi-Markov networks. New parametric models address censored data, improving survival and hazard function estimation for clinical trials.

Keywords:
CIF extrapolationKaplan-Meier integralcumulative incidencemultistate modelsaddlepoint approximationsemi-Markov network

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

2.9K

Related Experiment Videos

Last Updated: May 4, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.9K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

2.9K

Area of Science:

  • Biostatistics
  • Survival Analysis
  • Clinical Trial Methodology

Background:

  • Transform methods are effective for analyzing event progression in semi-Markov networks.
  • Censored data in clinical trials poses significant challenges for traditional transform methods.
  • Nonparametric methods struggle with estimating transforms in states truncated by end-of-study censoring.

Purpose of the Study:

  • To propose and evaluate parametric models for residual survival to address censored data in semi-Markov networks.
  • To adapt transform inversion methods for situations with end-of-study censoring.
  • To demonstrate the feasibility and efficiency of the proposed methods in a real-world clinical trial.

Main Methods:

  • Calculated transforms of time to a terminating event from intermediate steps in semi-Markov networks.
  • Employed saddlepoint inversion to derive survival and hazard functions.
  • Utilized parametric models specifying residual survival and imposed a proportional incidence assumption for extrapolation.
  • Applied transform inversion to data from the Long-Term Intervention with Pravastatin in Ischaemic Disease study.

Main Results:

  • The proposed parametric approach successfully handles censored data, enabling estimation of survival and hazard functions.
  • Transform inversion integrates network data, including transition probabilities and empirical survival distributions.
  • The method demonstrated feasibility and efficiency in a large randomized controlled trial.
  • Inferences derived from transform inversion were sharper than traditional log-rank methods when intermediate events were ignored.

Conclusions:

  • Parametric models with residual survival specification offer a viable solution for transform methods in the presence of censored data.
  • Transform inversion provides a powerful tool for analyzing multistate models, integrating diverse data components.
  • The approach allows for forecasting survival and hazard functions beyond the observed follow-up period.
  • This method offers improved statistical inference compared to methods that disregard intermediate events in survival analysis.